UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37835 Indivior Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) State or other jurisdiction of incorporation or organization Delaware 41-2520873 (I.R ...

Indivior (NasdaqGS:INDV) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristian Glennie - DirectorJason Thompson - VP of Investor RelationsJoe Ciaffoni - CEO and DirectorPatrick Barry - CCORyan Preblick - CFOThibault Boutherin - Equity Research - Executive DirectorConference Call ParticipantsBrandon Folkes - Managing Director and Senior Equity Research AnalystChase Knickerbocker - Senior Equity Research AnalystDavid Amsellem - Managing Director and Senior Research AnalystDennis Di ...

Indivior (NasdaqGS:INDV) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristian Glennie - DirectorJason Thompson - Vice President, Investor RelationsJoe Ciaffoni - CEOPatrick Barry - Chief Commercial OfficerRyan Preblick - CFOThibault Boutherin - Equity Research - Executive DirectorConference Call ParticipantsBrandon Folkes - Managing Director and Senior Equity Research AnalystChase Knickerbocker - Senior Equity Research AnalystDavid Amsellem - Managing Director and Senior Researc ...

Indivior, Powering Recovery, Renewing Hope. Q4 and FY 2025 Financial Results February 26, 2026 IMPORTANT CAUTIONARY STATEMENT REGARDING FORWARD- LOOKING STATEMENTS Execution Against the Indivior Action Agenda Joe Ciaffoni, CEO Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking stat ...

Exhibit 99.1 Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results Richmond, VA, February 26, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "In 2025 we successfully completed Phase I of the Indivior Action Agenda – Generate Momentum," said Joe Ciaffoni, Chief Executive Officer. "We sharpened our focus on our highest growth opportunity, U.S. SUBLOCADE, estab ...

Indivior, Powering Recovery, Renewing Hope. Investor Presentation February 26, 2026 IMPORTANT CAUTIONARY STATEMENT REGARDING FORWARD- LOOKING STATEMENTS This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company's financial guidance for 2026, including total net revenue, SUBLOCADE® net revenue, non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, and cash flow from opera ...

Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Fina ...

RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to sche ...

RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materia ...

Core Viewpoint - Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, establishing a new parent company in Delaware and renaming the previous entity to Indivior Ltd, which is now a wholly-owned subsidiary [1][2] Group 1: Redomiciliation Details - The redomiciliation was approved by Indivior shareholders during an extraordinary general meeting on December 11, 2025 [1] - Indivior PLC ordinary shares ceased trading on Nasdaq on January 23, 2026, with shareholders receiving one new common share of Indivior Pharmaceuticals, Inc. for each share held [1] Group 2: Benefits of Redomiciliation - The change in domicile is expected to enhance the benefits of its US stock listing, including compliance with SEC reporting requirements and Nasdaq exchange rules [2] - The company anticipates potential inclusion in additional US equity indices, which could strengthen its market presence [7] - Simplification of corporate governance and reduced complexity are also expected outcomes of the redomiciliation [7] Group 3: Strategic Positioning - The redomiciliation aims to further position Indivior as a US-based treatment innovator, facilitating closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder [7] - Indivior is committed to delivering evidence-based treatment for opioid use disorder and advancing the understanding of this condition as a chronic but treatable brain disease [5]